Mediators of inflammation · 2026
Biomarkers in QuantiFERON Supernatants May Help Distinguish Latent Tuberculosis Infection From Active Tuberculosis: Preliminary Report.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Borkowska-Tatar Dagmara, Zabost Anna, Czopowicz Michał, Augustynowicz-Kopeć Ewa
Аннотация
BACKGROUND: Latent tuberculosis infection (LTBI) is an important public health problem and a major source of future active tuberculosis (ATB) cases. In this preliminary study, we sought to identify host biomarkers that could potential differentiate between LTBI and ATB.
METHODS: A total of 145 plasma samples obtained from antigen tubes of the QuantiFERON-TB Gold Plus assay were analysed. Concentrations of 20 selected cytokines were determined using a multiplex bead-based immunoassay (Luminex xMAP Technology). Cytokine profiles were compared between patients with ATB, LTBI, and non-tuberculosis (TB)/LTBI controls. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis and multivariable logistic regression modelling.
RESULTS: Comparison of cytokine profiles showed significant differences in 13 of 20 analysed markers between LTBI and ATB. Among all evaluated biomarkers, interleukin-7 (IL-7) demonstrated the highest diagnostic potential in differentiating the two conditions (95.9%), outperforming interferon-gamma (IFN-γ), the key component of current IFN-γ release assay (IGRA) assays. A logistic regression model based on IL-7 and IFN-γ achieved high diagnostic accuracy (98.1%) in this study cohort.
CONCLUSION: These preliminary findings suggest that IL-7, in combination with IFN-γ, may serve as a promising candidate biomarker signature for distinguishing LTBI from ATB. Nevertheless, these findings are based on a single-centre dataset and represent internal, non-externally validated results. Therefore, external validation in independent multicentre cohorts is essential before any clinical application can be considered.
METHODS: A total of 145 plasma samples obtained from antigen tubes of the QuantiFERON-TB Gold Plus assay were analysed. Concentrations of 20 selected cytokines were determined using a multiplex bead-based immunoassay (Luminex xMAP Technology). Cytokine profiles were compared between patients with ATB, LTBI, and non-tuberculosis (TB)/LTBI controls. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis and multivariable logistic regression modelling.
RESULTS: Comparison of cytokine profiles showed significant differences in 13 of 20 analysed markers between LTBI and ATB. Among all evaluated biomarkers, interleukin-7 (IL-7) demonstrated the highest diagnostic potential in differentiating the two conditions (95.9%), outperforming interferon-gamma (IFN-γ), the key component of current IFN-γ release assay (IGRA) assays. A logistic regression model based on IL-7 and IFN-γ achieved high diagnostic accuracy (98.1%) in this study cohort.
CONCLUSION: These preliminary findings suggest that IL-7, in combination with IFN-γ, may serve as a promising candidate biomarker signature for distinguishing LTBI from ATB. Nevertheless, these findings are based on a single-centre dataset and represent internal, non-externally validated results. Therefore, external validation in independent multicentre cohorts is essential before any clinical application can be considered.